Back to Back Issues Page
Implant for Sustained Delivery or Monthly Eye Injections?
April 19, 2017

Implant for Sustained Delivery or Monthly Eye Injections?

What would you prefer? Monthly eye injections to treat your wet macular degeneration (AMD) or an implant that delivered your anti-VEGF drug without monthly visits to your eye doctor? Genentech, the drug company that makes Lucentis (Ranibizumab) is enrolling patients in a Phase II trial to determine the efficacy of delivering Lucentis via a tiny implant about the size of a grain.

Implantable Device for Drug Delivery

Currently Lucentis is FDA approved to treat wet AMD where fragile, irregular blood vessels that leak fluid and blood grow under the macula resulting in vision loss. However, the treatment protocol often requires monthly visits to the retina specialist which can be a burden for many patients. For those who are unable to comply, more vision loss can occur.

"The hope being the sustained delivery program would be that you would have a device such as ours that could be placed in the eye, could release drugs over longer periods of time and really decrease that burden of office visits and regular injections while most importantly still maintaining good levels of vision," states Jill Hopkins, medical director of Ophthalmology at Genentech.

Find out who qualifies for this Phase II trial and the study locations that are recruiting new patients:

Sustained Release Delivery of Lucentis using Implantable Device

Leslie Degner, RN, BSN

Better Health for Better Vision

Back to Back Issues Page